InSightec Ltd

TIRAT CARMEL, Israel, November 27, 2011 - - Evidence Sufficient to Support the Use of This Procedure With Normal Arrangements - InSightec Ltd announced that NICE, the National Institute for Health and Clinical Excellence of the NHS in the UK, announced new favorable guidelines for the treatment of uterine fibroids using MR guided Focused Ultrasound.

TIRAT CARMEL, Israel, September 21, 2011 - InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that its investigational ExAblate Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.

TIRAT CARMEL, Israel, July 13, 2011 - Initial Results are Encouraging, Spurring Hope for a Treatment Option With a Lower Rate of Complications InSightec Ltd., the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate system for treating uterine fibroids, announced today that 23 patients with organ confined low risk prostate cancer have already been treated with its ExAblate system in clinical trials, showing promising initial results.

TIRAT CARMEL, Israel, September 29, 2010 - InSightec Ltd., the global leader in MR guided Focused Ultrasound technology (MRgFUS) announced today that it will be launching ExAblate(R) One for the treatment of uterine fibroids, adenomyosis and research options in women's health and the ExAblate(R) OR system as the Operating Room of the future at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010 meeting.

TIRAT CARMEL, Israel, August 31, 2010 - InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.